抗Human ErbB3/Her3抗体(Anti-Human ErbB3/Her3 antibody)

• 価格
• Product Details
• Applications and Data
• Data Examples
• References
• Related Research Areas
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	Mouse myeloma cell line NS0-derived recombinant human ErbB3/Her3Ser20-Thr643Accession # P21860
Source	Monoclonal Mouse IgG1 Clone # 66223
Purification	Protein A or G purified from hybridoma culture supernatant
Specificity	Detects human ErbB3/Her3 in ELISAs. Does not cross-react with recombinant EGF R.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Flow Cytometry	2.5 µg/106 cells	MCF‑7 human breast cancer cell line
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Human ErbB3/Her3 Sandwich Immunoassay	Reagent
ELISA Capture (Matched Antibody Pair)	2-8 µg/mL	Human ErbB3/Her3 Antibody (Catalog #MAB3481 )
ELISA Detection (Matched Antibody Pair)	0.5-2.0 µg/mL	Human ErbB3/Her3 Biotinylated Antibody (Catalog #BAM348 )
ELISA Standard		Recombinant Human ErbB3/Her3 Fc Chimera Protein, CF (Catalog #348-RB )
Neutralization	Measured by its ability to neutralize NRG1‑ beta 1/HRG1‑ beta 1-induced proliferation in the MCF‑7 human breast cancer cell line. The Neutralization Dose (ND50) is typically 0.0075-0.03 µg/mL in the presence of 10 ng/mL Recombinant Human NRG1‑ beta 1/HRG1‑ beta 1 Extracellular Domain.
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.

目次に戻る

Data Examples

Neutralization	click image to view larger	Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human ErbB3/Her3 Antibody.Recombinant Human NRG1‑1 beta 1/HRG1‑1 beta 1 (Catalog # 377-HB) stimulates proliferation in the MCF‑17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1‑1 beta 1/HRG1‑1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND50 is typically 0.0075-0.03 µg/mL.
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.	Reconstitution Buffer Available
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: ErbB3/Her3	ErbB3, also called Her3 (human epidermal growth factor receptor 3), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. Among ErbB family members, ErbB3 is unique in that it contains a defective kinase domain. ErbB3 is expressed in keratinocytes, melanocytes, skeletal muscle cells, embryonic myoblasts and Schwann cells. Monomeric ErbB3 serves as a low affinity receptor for the heregulins (HRG). ErbB3 heterodimerizes with ErbB2 to form a high affinity receptor complex. In contrast, ErbB3 homodimerization or heterodimerization with ErbB4 forms a low affinity heregulin-binding complex. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. The cytoplasmic domain of ErbB3 also contains six consensus binding motifs for the SH2 domain of the regulatory p85 subunit of phosphoinositide 3-kinase (PI 3-kinase, PI3K) as well as one proline-rich consensus binding motif for the SH3 domain of p85. Human ErbB3 consists of 1342 amino acids (aa) with a 19 aa signal sequence, a 624 aa extracellular domain, a 21 aa transmembrane region, and a 678 aa cytoplasmic domain. ErbB3 appears to play roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation.

目次に戻る

References

Kraus, M.H. et. al. (1989) Proc. Natl. Acad. Sci. USA 86:9193.
Plowman, G.D. et. al. (1990) Proc. Natl. Acad. Sci. USA 87:4905.
Carraway, K.L. 3rd et. al. (1994) J. Biol. Chem. 269:14303.
Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
Sundaresan, S. et. al. (1998) Endocrinology 139:4756.
Hellyer, N.J. et. al. (1998) Biochem. J. 333:757.
Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859.
Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
Schlessinger, J. (2000) Cell 103:211.
Daly, R.J. (1999) Growth Factors 16:255.
Long Name:	Receptor Tyrosine Protein Kinase ErbB3
Entrez Gene IDs:	2065 (Human); 13867 (Mouse)
Alternate Names:	c-erbB3; EC 2.7.10; EC 2.7.10.1; ErbB3; ErbB-3; erbB3-S; HER3; HER3c-erbB-3; LCCS2; lethal congenital contracture syndrome 2; MDA-BF-1; MGC88033; p180-ErbB3; p45-sErbB3; p85-sErbB3; Proto-oncogene-like protein c-ErbB-3; receptor tyrosine-protein kinase erbB-3; Tyrosine kinase-type cell surface receptor HER3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

目次に戻る

Related Research Areas

Cancer Biomarkers

EGF Family

Receptor Tyrosine Kinases (RTKs)

Receptor Tyrosine Kinases (RTKs) in the Akt Pathway

Soluble HER3 predicts survival in bladder cancer patients Authors: AA Memon, SC Gilliver, M Borre, J Sundquist, K Sundquist, E Nexo, BS Sorensen Oncol Lett, 2018;15(2):1783-1788. Species: Human Sample Type: Plasma Application: ELISA Capture

Neutralization

Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human ErbB3/Her3 Antibody. Recombinant Human NRG1‑1 beta 1/HRG1‑1 beta 1 (Catalog # 377-HB) stimulates proliferation in the MCF‑17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1‑1 beta 1/HRG1‑1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND50 is typically 0.0075-0.03 µg/mL.

目次に戻る

Related Product & Information

Long Name	Receptor Tyrosine Protein Kinase ErbB3
Entrez Gene IDs	2065 (Human); 13867 (Mouse)
Background	ErbB3/Her3
background_content	Background: ErbB3/Her3 ErbB3, also called Her3 (human epidermal growth factor receptor 3), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. Among ErbB family members, ErbB3 is unique in that it contains a defective kinase domain. ErbB3 is expressed in keratinocytes, melanocytes, skeletal muscle cells, embryonic myoblasts and Schwann cells. Monomeric ErbB3 serves as a low affinity receptor for the heregulins (HRG). ErbB3 heterodimerizes with ErbB2 to form a high affinity receptor complex. In contrast, ErbB3 homodimerization or heterodimerization with ErbB4 forms a low affinity heregulin-binding complex. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. The cytoplasmic domain of ErbB3 also contains six consensus binding motifs for the SH2 domain of the regulatory p85 subunit of phosphoinositide 3-kinase (PI 3-kinase, PI3K) as well as one proline-rich consensus binding motif for the SH3 domain of p85. Human ErbB3 consists of 1342 amino acids (aa) with a 19 aa signal sequence, a 624 aa extracellular domain, a 21 aa transmembrane region, and a 678 aa cytoplasmic domain. ErbB3 appears to play roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation.

目次に戻る

Citations

1. Soluble HER3 predicts survival in bladder cancer patients
   Authors: AA Memon, SC Gilliver, M Borre, J Sundquist, K Sundquist, E Nexo, BS Sorensen
   Oncol Lett, 2018;15(2):1783-1788.
   Species: Human
   Sample Type: Plasma
   Application: ELISA Capture


2. Neuregulin 1 allosterically enhances the anti-tumor effects of the non-competing anti-HER3 antibody 9F7-F11 by increasing its binding to HER3
   Authors: C Le Clorenn, H Bazin, O Dubreuil, C Larbouret, C Ogier, Y Lazrek, V Garambois, MA Poul, P Mondon, JM Barret, G Mathis, JF Prost, A Pèlegrin, T Chardès
   Mol. Cancer Ther., 2017;0(0):.
   Species: Human
   Sample Type: Recombinant Protein
   Application: ELISA Development


3. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
   Authors: Helmout Modjtahedi
   Int. J. Oncol., 2016;49(5):1825-1838.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


4. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.
   Authors: Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz I, Yan W
   J Biol Chem, 2015;290(12):7535-62.
   Species: Human
   Sample Type: Whole Cells
   Application: ELISA Capture


5. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation
   Authors: V Fock, K Plessl, P Draxler, GR Otti, C Fiala, M Knöfler, J Pollheimer
   J. Cell. Sci, 2015;128(23):4306-16.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


6. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
   Authors: Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H
   Int. J. Oncol., 2011;39(2):483-91.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


7. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
   Authors: Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA
   Assay Drug Dev Technol, 2010;8(1):27-36.
   Species: Human
   Sample Type: Cell Lysates
   Application: IP


8. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
   Authors: Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ
   Oncogene, 2008;27(39):5195-203.
   Species: Human
   Sample Type: Plasma
   Application: ELISA Development


9. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
   Authors: Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ
   Clin. Cancer Res., 2008;14(12):3729-36.
   Species: Human
   Sample Type: Cell Culture Supernates
   Application: ELISA Development

目次に戻る